MIRALAX (polyethylene glycol 3350) by ANI Pharmaceuticals is osmotic activity [moa]. First approved in 1999.
Drug data last refreshed 5d ago
MIRALAX is an oral osmotic laxative containing polyethylene glycol 3350 that draws water into the bowel to soften stool and promote bowel movements. It is indicated for chronic idiopathic constipation, opioid-induced constipation, and bowel preparation. The drug works through osmotic activity, increasing stool water content without systemic absorption.
As LOE approaches, brand team size will contract; focus shifts to line extensions, consumer marketing, and defending market share against newer active comparators.
Osmotic Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)
Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)
Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
Worked on MIRALAX at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MIRALAX offers limited growth potential as the product approaches loss of exclusivity and faces competition from newer, more innovative mechanisms. This role suits professionals seeking stability in a mature market or those building foundational brand management experience in a lower-risk, high-volume asset.